STERIS's (STE) "Hold" Rating Reiterated at Needham & Company LLC

STERIS (NYSE:STE - Get Free Report)'s stock had its "hold" rating reiterated by analysts at Needham & Company LLC in a research note issued to investors on Monday,Benzinga reports.

Several other analysts have also recently issued reports on the stock. JMP Securities reaffirmed a "market outperform" rating and set a $265.00 price objective on shares of STERIS in a research note on Thursday, February 6th. Piper Sandler upped their price target on STERIS from $260.00 to $265.00 and gave the company an "overweight" rating in a research report on Monday, February 3rd. Finally, Stephens reaffirmed an "overweight" rating and issued a $240.00 price target on shares of STERIS in a report on Thursday, February 6th. One research analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. According to data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $258.75.

STERIS Price Performance

STERIS stock traded up $4.06 during midday trading on Monday, reaching $221.18. The company had a trading volume of 459,313 shares, compared to its average volume of 535,699. STERIS has a 12-month low of $197.82 and a 12-month high of $248.24. The firm's fifty day simple moving average is $222.61 and its 200-day simple moving average is $219.62. The company has a debt-to-equity ratio of 0.32, a current ratio of 2.13 and a quick ratio of 1.40. The company has a market capitalization of $21.73 billion, a P/E ratio of 46.96 and a beta of 0.87.

Remove Ads

STERIS (NYSE:STE - Get Free Report) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $2.32 earnings per share for the quarter, missing the consensus estimate of $2.33 by ($0.01). STERIS had a net margin of 8.66% and a return on equity of 13.91%. As a group, equities analysts anticipate that STERIS will post 9.08 EPS for the current year.

Institutional Investors Weigh In On STERIS

Large investors have recently bought and sold shares of the stock. Avalon Trust Co acquired a new stake in shares of STERIS during the 4th quarter worth about $30,000. Human Investing LLC purchased a new position in STERIS in the 4th quarter valued at $31,000. Anfield Capital Management LLC increased its stake in shares of STERIS by 100.0% during the fourth quarter. Anfield Capital Management LLC now owns 182 shares of the medical equipment provider's stock worth $37,000 after acquiring an additional 91 shares during the period. Central Pacific Bank Trust Division increased its position in STERIS by 65.5% during the 4th quarter. Central Pacific Bank Trust Division now owns 192 shares of the medical equipment provider's stock worth $39,000 after purchasing an additional 76 shares during the period. Finally, Manchester Capital Management LLC raised its position in STERIS by 182.7% in the fourth quarter. Manchester Capital Management LLC now owns 212 shares of the medical equipment provider's stock worth $44,000 after acquiring an additional 137 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company's stock.

STERIS Company Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.